Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURPASS J-combo: Tirzepatide Safety Study in Japanese T2D Patients
NCT03861039Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2019
- Primary completion
- Jan 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tirzepatide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration at 52 weeks. Started Mar 2019; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03861039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03861039.